The status of the p53 pathway in classical Hodgkin lymphoma (cHL) remains unclear, and a lack of proven TP53 mutations contrasts with often high expression levels of p53 protein. In this study, we demonstrate that pharmacologic activation of the p53 pathway with the murine double minute 2 (MDM2) antagonist nutlin-3 in Hodgkin lymphoma-derived cell lines leads to effective apoptosis induction and sensitizes the cells to other anticancer drugs. Cells with mutant p53 are resistant to nutlin-3, but sensitive to geldanamycin, a pharmacologic inhibitor of heat shock 90 kDa protein (HSP90), indicating that HSP90 inhibition can induce apoptosis in a p53-independent manner. Conversely, cells with defects in the HSP90/nuclear factor-j B pathway expressing wild-type p53 are more resistant to geldanamycin, but still sensitive to nutlin-3. Our results suggest that selective activation of p53 by MDM2 antagonists as a single agent or in combination with conventional chemotherapeutics and/or inhibitors of p53-independent survival pathways may offer effective treatment options for patients with cHL. Importantly, because nutlins and HSP90 inhibitors are non-genotoxic agents, their use might offer a means to reduce the genotoxic burden of current chemotherapeutic regimens.
Introduction
Classical Hodgkin lymphoma (cHL) is a common neoplastic disease that is characterized by the signature presence of mononuclear Hodgkin and multinuclear Reed-Sternberg (HRS) cells. 1 Nowadays, cHL has a good prognosis and up to 90% of patients can be cured through polychemotherapy and radiotherapy. However, this therapeutic success is linked with considerable long-term toxicity, especially a substantially increased risk for the development of second malignancies. 2, 3 The therapeutic activity of conventional cancer therapies is a trade-off between efficacy and adverse effects, such as genotoxic damage that increases the risk of oncogenic mutation, genetic instability, development of resistant tumor subclones, and second malignancies. Therefore, the development of strategies to achieve cancer cell death through non-genotoxic mechanisms is highly desirable.
Recently, a novel class of small-molecule antagonists of murine double minute 2 (MDM2), the main cellular inhibitor of tumor suppressor protein p53 (encoded by the TP53 gene), has been shown to induce growth arrest and apoptosis in cancer cells that retain wild-type p53. [4] [5] [6] [7] MDM2 serves to maintain very low levels of p53 by tagging it for proteosomal degradation, and because the gene for MDM2 is itself a transcriptional target of p53 a rise in p53 levels leads to immediate replenishment of its inhibitor. 8 If this balance between p53 and MDM2 becomes disturbed, for example through DNA damage induced by genotoxic drugs, elevated cellular levels of p53 can lead to cell cycle arrest (largely mediated through transcriptional activation of the gene for p21 WAF ) and to apoptosis. MDM2 inhibitors therefore permit a functional analysis of the p53-MDM2 checkpoint in tumor cells and may enable specific, nongenotoxic activation of the p53 apoptotic pathway in tumors with wild-type p53. Although mutation of TP53 is one of the most frequent events during cancerogenesis, its prevalence differs considerably between cancers. 9 In cHL, TP53 mutations are rarely found, [10] [11] [12] suggesting that activation of the p53 pathway could be an effective therapeutic approach for this malignancy.
HRS cells maintain high constitutive activity of the transcription factor NF-kB (nuclear factor-kB). 13 The reasons for this are not completely understood, but inactivating mutations of its inhibitor, IkB, may be involved in a proportion of cases. 14, 15 Furthermore, blockade of the molecular chaperone heat shock 90 kDa protein (HSP90), which stabilizes a range of signaling pathways important for cancer cell proliferation and survival, has been shown to decrease the activity of NF-kB in HRS cells that harbor unmutated IkB protein. 16 Because pharmacologic inhibition of HSP90 represents another non-genotoxic means to induce cancer cell death, 17 we tested the susceptibility of HRS cells for treatment with geldanamycin. Our work suggests that selective non-genotoxic pharmacologic activation of p53-dependent and p53-independent apoptotic pathways could be an option for effective but less damaging treatment strategies for cHL.
Materials and methods

Cell culture
Hodgkin lymphoma-derived cell lines L428, L1236, KM-H2, L591, HDLM-2, L540 and L540Cy were maintained in Roswell Park Memorial Institute 1640, supplemented with 10% fetal bovine serum (both from Biochrom, Berlin, Germany), 100 U/ml penicillin, 100 mg/ml streptomycin (both from PAN Biotech, Aidenbach, Germany), 2 mM glutamine and 1 mM Na-pyruvate (both from Gibco, Karlsruhe, Germany). All cells were grown at 371C and 5% CO 2 . L540Cy (a subline of L540) was kindly provided by A Engert (University Hospital Cologne, Germany). L591 cells were obtained from the group of V Diehl (University Hospital Cologne, Germany). The other lines had been purchased at the DSMZ (Braunschweig, Germany).
Electroporation
Electroporation of L540Cy cells was performed using a GenePulser II (Bio-Rad, Munich, Germany) with settings of 960 mF and 0.18 kV (500 ml cell suspension, electrode distance 0.4 cm). Analysis and separation of transfected cells were performed as detailed by Chatterjee et al., 18 except that transfected cells were purified with MACSelect K k Microbeads (Miltenyi Biotech, Bergisch, Gladbach, Germany).
Construction of p53 siRNA expression plasmid
The vector for transient expression of p53 siRNA was constructed exactly as described by Brummelkamp et al.
19
Control experiments were performed with the empty pSUPER plasmid or an siRNA expression plasmid against ERK1. 18 
Analysis of cell survival and apoptosis
Drug sensitivity assays were performed in 96-well plates. Cells (1 Â 10 4 ) were seeded and incubated for 3 days in 200 ml medium containing the respective compound. The live cell fraction was determined by staining with annexin V-fluorescein isothiocyanate/propidium iodide (annexin V-FITC/PI) and flow cytometry (FACSCalibur, Becton Dickinson, Heidelberg, Germany). The cell population in the lower left quadrant, negative for annexin V-FITC and PI, was counted as the live cell fraction. Relative survival in each assay was calculated as the percentage of the live cell fraction relative to those in dimethylsulfoxide (DMSO)-treated control assays, designated as 100%. To analyze the effects of combined treatment with nutlin-3a (or nutlin-3 in the case of cell line L591) and vincristine, etoposide or doxorubicin, cells were treated as if for sole incubation with the latter drugs, and after 2 days, half of the medium was exchanged for the same volume containing twice the desired concentration of nutlin-3(a), plus the applicable concentration of the respective genotoxic drug. Apoptosis was assessed 5 days after addition of the first drug. Caspase activation was analyzed by staining of nutlin-treated cells with FAM-DEVD-FMK as described in the manufacturer's protocol (Vybrant FAM caspase-3 and -7 assay kit; Invitrogen, Karlsruhe, Germany). To inhibit caspase activity, cells were incubated with 50 mM pan-caspase inhibitor Z-VAD-FMK (Calbiochem, Sehwalbach, Germany) before treatment with nutlin-3.
Western blot analysis
Procedures followed those detailed by Stü hmer et al. 5 Blots were cut apart and the different strips stained for MDM2, p53 or p21 WAF1 . Staining for b-actin was subsequently performed on the strip that also contained p53.
p53 Mutation analysis p53 cDNA sequence analysis was performed exactly as described by Stü hmer et al. 5 To determine cDNA sequence in cell lines with putative splicing defects, 3 0 -rapid amplification of cDNA ends (RACE) was performed as detailed by Harvey et al., 20 with primers 5-AGACTGCCTTCCGGGTCACT-3 0 (À23 to À4) and 5-ATGGCCATCTACAAGCAGTC-3 0 (477-496) as gene-specific primers in the first and second nests, respectively. Numbers refer to the human p53 cDNA sequence. Amplifications were for 25 (first nest) and 40 cycles (second nest). Second nest products were gel-purified and directly sequenced (HDLM-2), or sequenced after cloning into pGEM-T Easy (L1236).
Reagents
The following primary antibodies were used: anti-MDM2 (SC-965; Santa Cruz Biotechnology, Heidelberg, Germany), anti-p53 (BD-Pharmingen, Heidelberg, Germany, 554293), anti-p21 WAF1 (SC-397; Santa Cruz Biotechnology), anti-b-actin (Sigma, Deisenhofen, Germany, A5316). Anti-rabbit-HRP and anti-mouse-HRP (Promega, Mannheim, Germany, W4011, W4021) were used as secondary antibodies. Etoposide (341205), vincristine (677181) and doxorubicin (324380) were purchased from Calbiochem. Geldanamycin (ant-gl-1) was from Invivogen (Toulouse, France). Nutlin-3a and -3b were provided by Hoffmann-La Roche Inc. The racemic mixture nutlin-3 was purchased from Calbiochem (444143).
Data analysis
Dose-response curves were calculated from at least three independent experiments by nonlinear regression (variable slope dose-response curve) analysis using GraphPad Prism 3.0 (GraphPad Software).
Results
Inhibition of p53-MDM2 interaction with nutlin-3a activates p53 and induces apoptosis in Hodgkin cell lines with wild-type p53
We first examined the effects of MDM2 inhibition on the expression levels of p53 and two of its transcriptional targets in Hodgkin cell lines. Cells were incubated overnight with nutlin3a, which specifically blocks p53-MDM2 interaction. Control incubations with solvent DMSO and the inactive enantiomer nutlin-3b, which is approximately 150-fold less effective, 4 served to assess the background level of p53 and the specificity of nutlin-3a-mediated effects. Immunoblotting demonstrated constitutive p53 expression in all cell lines, albeit to varying degrees and with differences in migration pattern ( Figure 1a ). Specific upregulation of p53 protein after treatment with nutlin3a was observed in the cell (sub) lines KM-H2, L591, L540 and L540Cy ( Figure 1a ). The protein levels of MDM2 and p21
WAF1
were selectively increased in these four cell lines after treatment with nutlin-3a, indicating p53 transcriptional activity ( Figure 1a ).
To determine whether p53 activation would translate into an apoptotic response, Hodgkin cells were incubated with 10 mM of either nutlin-3 enantiomer, and cell death was assessed after 3 days. Induction of nutlin-3a-mediated apoptosis was observed only in those cell lines that displayed upregulation of p53 (Figure 1b) . In contrast, the viability of L428, L1236 or HDLM-2 cells, which did not show specific p53 induction, was virtually unaffected by nutlin-3a. Cell kill curves for the sensitive Hodgkin cell (sub) lines showed half-maximally effective concentrations (EC 50 ) in the low micromolar range (between 1.5 and 3.6 mM; Figure 1c) . To assess the role of caspase activation in nutlin-induced cell death, L428 and KM-H2 cells were treated with 20 mM nutlin-3, followed by staining with the fluorescent reagent FAM-DEVD-FMK that reacts with the enzymatic center of activated caspase-3 and -7, or by staining with annexin V-FITC. In contrast to nutlin-3-resistant L428 cells, the nutlin-sensitive cell line KM-H2 demonstrated a marked increase in FAM-DEVD-FMK-and annexin V-FITC-positive cells after 24 and 48 h (Figure 1d ). Furthermore, incubation of nutlin-3-sensitive L540 cells with the pan-caspase inhibitor Z-VAD-FMK before exposure to the MDM2 antagonist resulted in a significant reduction of nutlin-induced cytotoxicity (Figure 1e ).
Status of TP53 in Hodgkin cell lines
Hodgkin and Reed-Sternberg (HRS) cells often display elevated levels of p53. 21 However, on the basis of genetic analyses of Hodgkin cell lines and single primary tumor cells, it is generally assumed that this constitutes wild-type p53 protein. [10] [11] [12] It was thus unexpected that three Hodgkin cell lines were completely unaffected by nutlin-3a, and such unresponsiveness has so far only been observed in cells with mutant or deleted TP53. [4] [5] [6] [7] We therefore sequenced the complete coding region of TP53, PCRamplified from cDNA, for all HRS cell lines studied. This analysis confirmed wild-type TP53 cDNA sequence for KM-H2, L591, L540 and L540Cy, but revealed an in-frame deletion affecting bases 334-366 (which are part of exon 4 and encode amino acids 112-122) in L428 (Figure 1b) . Consistent with our observation that proper p53 synthesis appeared compromised in cell lines L1236 and HDLM-2, which displayed noticeably (Figure 1a) , PCR amplification with the primer pair specific for the 3-prime half of the p53 cDNA failed. For these cell lines, PCR products could be obtained with 3 0 -RACE, and their analysis showed that in HDLM-2 TP53 cDNA sequence was corrupted exactly after the part derived from exon 7. Genomically, the illegitimate sequence is found localized 12182 bases further downstream from exon 7 and it is preceded by a consensus 3 0 splice site. A deletion 3 0 of exon 7 has actually been noted before in genetic analyses of HDLM-2. 22 In L1236, the correct TP53 cDNA sequence was lost after that encoded by exon 9 and replaced by nucleotides located 7289 base pairs further downstream. This sequence, too, is preceded by a consensus 3 0 splice site. The predicted open reading frames for p53 in HDLM-2 and L1236 cells result in both cases in C-terminally corrupted and truncated proteins. The calculated molecular weights of 32 and 38 kDa, respectively (compared with 44 kDa for wild-type p53), correspond well with the aberrant migration pattern seen in Western analysis (Figure 1a) . The sequence aberrations detailed in this paragraph are represented in Supplementary Figure 1 . GenBank accession numbers for the mutant p53 cDNAs are EF101867 (L428), EF101868 (L1236) and EF101869 (HDLM-2).
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Induction of apoptosis by nutlin-3a is dependent on p53
To confirm that induction of apoptosis by nutlin-3a in Hodgkin cells is mediated via the p53 pathway, we knocked down p53 expression through RNA interference. TP53 wild-type L540 or L540Cy cells were transfected with a p53-directed siRNA expression plasmid, empty pSUPER vector or an innocuous siRNA expression construct against ERK1. Transfected cells were treated with 10 mM nutlin-3a or nutlin-3b, and apoptosis measurements were performed after 3 days. Expression of the p53 siRNA completely blocked constitutive p53 expression and strongly inhibited p53 induction following treatment with nutlin-3a (Figure 2a) . Moreover, knock down of p53 expression rendered L540Cy and L540 cells resistant to MDM2 inhibition, demonstrating that nutlin-3a exerts its effects via p53 (Figure 2a and b).
Combined treatment with nutlin-3a and cytotoxic drugs strongly enhances apoptosis of Hodgkin cells
Because many antineoplastic agents exert their apoptotic effects at least in part through activation of p53, we asked whether combination with MDM2 antagonists would increase their antitumor activity in HRS cells. We therefore compared the cytotoxicities of nutlin-3a and three commonly used drugs in the TP53 wild-type Hodgkin cell lines L540, KM-H2 and L591 (Figure 3 ). In every cell line, vincristine was the most potent compound (EC 50 ¼ 1-5 nM), followed by doxorubicin (EC 50 ¼ 20-50 nM), etoposide (EC 50 ¼ 100-220 nM), and nutlin3a (EC 50 ¼ 1.5-3.6 mM). We then tested these drugs in combination with nutlin-3a (or with nutlin-3 in the case of L591) at concentrations at which any single agent causes only minor apoptotic effects. Five-day incubations, with nutlin-3(a) added for the last 3 days, led to much stronger decreases in survival than any comparable single drug treatment alone in every cell line tested (Figure 4 ). These observations suggest that a combination of MDM2 antagonist with chemotherapeutic agents might potentially offer a way to achieve significant dose reductions of the latter without compromising treatment efficacy.
The HSP90 inhibitor geldanamycin efficiently induces cell death in mutant TP53 HRS cells
Recently, it has been shown that HSP90 maintains constitutive signaling of the major survival factor NF-kB in HRS cells by promoting IkB kinase (IKK) biosynthesis and activity. 16 We Figure 2 Induction of apoptosis by nutlin-3a is dependent on p53. (a) L540Cy cells were transfected with the siRNA expression vector pSUPERp53 (pSU-p53), which knocks down p53, or with empty control vector (pSU). MACS-purified transfected cells were treated with 5 mM nutlin-3a (N3a) or nutlin-3b (N3b) for 3 days. p53 protein expression was determined by Western blot analysis. Viability was assessed by annexin V-FITC/PI staining and flow cytometry. (b) L540 cells were co-transfected with pEGFP-N3 and pSUPER (pSU), pSUPER-p53 (pSU-p53) or pSUPER-ERK1 (pSU-ERK1), which knocks down one of the two homologous forms of extracellular signal-regulated kinase (ERK). Two days after electroporation, 10 mM nutlin-3 was added (t ¼ 0 h) and cell survival assessed after another 3 days. Only p53 knock-down cells managed to survive exposure to nutlin-3.
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M Janz et al therefore asked whether pharmacologic inhibition of HSP90 induces apoptosis in HRS cells and whether this effect is dependent on intact p53 signaling. To this end, we treated wildtype TP53 (KM-H2, L540, L540Cy) and mutant TP53 (L1236, L428, HDLM-2) HRS cells with geldanamycin, a selective pharmacologic inhibitor of HSP90. Induction of apoptosis by geldanamycin was apparently not related to the mutation status of TP53, because both wild-type (L540, L540Cy) and mutant (L1236, HDLM-2) HRS cells were competent to execute apoptotic responses (Figure 5a ). Two cell lines, again representing wild type (KM-H2) and mutant (L428) TP53, were less sensitive to geldanamycin treatment and were only partially affected even by higher concentrations of the drug. Both cell lines harbor loss of function defects for IkBa (KM-H2) or IkBa and IkBe (L428), which contribute to NF-kB activation independent of IKK activity. Conversely, all geldanamycinsensitive cells contain wild-type IkB protein. 14, 15 To address the relationship between NF-kB inhibition and geldanamycininduced cytotoxicity, we transfected L540Cy cells with an NF-kB p65 expression construct to maintain a high level of NF-kB-binding activity. 23 Transient overexpression of NF-kB p65 resulted in a significant protection from geldanamycininduced cell death (Supplementary Figure) . Thus, sensitivity to pharmacologic inhibition of HSP90 could be modulated by the functional status of IkB/NF-kB signaling, whereas no correlation with the TP53 mutation status is apparent.
To confirm that geldanamycin-induced apoptosis is p53-independent, we performed siRNA-mediated p53 knock-down in L540Cy cells which are sensitive to geldanamycin and nutlin3a. As demonstrated in Figure 2a , selective knock down of p53 led to almost complete resistance of L540Cy cells against nutlin treatment. In contrast, their sensitivity to geldanamycin-induced apoptosis remained largely unaffected (Figure 5b ).
Discussion
Many drugs currently used in cancer treatment exert their antineoplastic effects at least in parts via induction of p53-dependent apoptotic pathways. However, this apoptotic response is triggered by unspecific DNA damage. Therefore, treatments with genotoxic agents harbor the risk of inducing additional oncogenic events. Selective non-genotoxic activation of the p53 apoptotic pathway could thus be an attractive therapeutic strategy for cancers that retain wild type, transcriptionally competent p53.
In cHL, the genetic and functional status of the p53 pathway is still not fully understood. Immunohistochemical analyses have demonstrated that primary HRS cells contain high levels of p53 protein, 21 an observation that is often indicative of p53 mutation. 24 However, on the basis of analysis of micromanipulated primary HRS cells, TP53 defects appear to be rare, [10] [11] [12] suggesting that other mechanisms are responsible for the accumulation of p53 protein in cHL. Moreover, it was unclear whether the p53-dependent apoptotic pathways remain functionally intact in HRS cells.
Treatment with the selective MDM2 antagonist nutlin-3a induced elevated levels of p53, and of MDM2 and p21 WAF1 , whose genes are transcriptional targets of p53, in four of the HRS cell lines studied. Only cells with a functional response to nutlin-3a displayed apoptosis, and subsequently TP53 defects were found in each of the three drug-resistant cell lines. Knock down of wild-type p53 in nutlin-sensitive HRS cells rendered them resistant. These observations confirm the high target specificity of nutlin-3a and show that nutlin-mediated apoptosis in HRS cells is strictly dependent on p53 activation. They also suggest that pharmacologic disruption of p53-MDM2 binding may be sufficient to induce cell death in HRS cells with wildtype p53. This situation is similar to observations in other hematologic cancers, 5, 6 although the correlation between p53 activation and apoptosis induction is not universally encountered in wild-type p53 cell lines derived from solid tumors. 7 Combination of nutlin-3a with antineoplastic drugs (e.g. doxorubicin, etoposide or vincristine), which are used in the treatment of cHL, revealed greater than additive apoptosis induction in p53 wild-type HRS cells. This suggests that combination treatment of cHL with MDM2 antagonists could effectively reduce the therapeutic dose of genotoxic drugs.
Although TP53 mutations are rarely found in cHL, we detected mutations in three HRS cell lines. Because such cell Figure 3 Activity of nutlin-3a and of cytotoxic drugs on wild-type TP53 HRS cell lines. L540, KM-H2 and L591 cells were treated with vincristine, doxorubicin, etoposide or nutlin-3a to determine the respective kill curves. Cells were exposed to each drug at the indicated concentrations for 3 days and survival was assessed by annexin V-FITC/PI staining and flow cytometry.
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M Janz et al lines are usually derived from malignant cell populations of advanced stage disease, this observation may indicate that, as in other hematologic cancers, 9 TP53 mutation is more prominent in refractory cHL. However, it should also be noted that all three mutations observed in this study involve larger scale loss of TP53 coding sequence, as opposed to the more commonly reported point mutations. Furthermore, the location in exon 4 (L428) as well as the association with splice junctions (HDLM-2, L1236) suggest that mutation analysis of TP53 via the common practice of exons 5-8 specific PCR [10] [11] [12] 22 may be insufficient for a proper assessment. For example, whereas this analysis was sufficient to detect the TP53 abnormality in HDLM-2, the defect in L428 was missed. 22 It is thus possible that the frequency of TP53 defects has been underestimated in cHL, at least in advanced and refractory forms of the disease.
Because of possible resistance to p53-activating drugs it is of interest to identify pharmacologic targets that involve p53-independent apoptotic mechanisms. We focused our analysis on HSP90 which is required for constitutive activation of the IKK/ IkB/NF-kB survival pathway in HRS cells. 13, 16 HSP90 is a constitutively expressed molecular chaperone which is overexpressed in many cancers and possibly required to sustain aberrant signaling in malignant cells. Pharmacologic inhibition of HSP90 can induce apoptosis in a variety of tumors. 17 Here, we show that treatment with geldanamycin efficiently induces apoptosis in all Hodgkin cell lines with wild-type IkB, whereas cells from two lines that contain mutant IkBa and/or IkBe appear partially resistant. This corresponds to observations by Broemer et al., 16 who saw geldanamycin-induced inhibition of NF-kB only in HRS cells with wild-type IkBa, but not in those with IkBa mutation, suggesting that at least some of the HSP90 prosurvival effects could be mediated via the IKK/IkB/NF-kB pathway. Such a notion is supported by our observation that transient overexpression of NF-kB p65 efficiently protected L540Cy cells from geldanamycin-induced cell death. Our experiments confirm observations by Georgakis et al., 25 who described Figure 4 Treatment of HRS cells with nutlin-3(a) in addition to chemotherapeutic agents strongly enhances apoptotic effects. Wild-type TP53 cells were exposed for 5 days to low concentrations of the conventional cytotoxic drugs doxorubicin (Dox), etoposide (Eto) or vincristine (Vin), with low concentrations of nutlin-3a (or nutlin-3 in the case of L591) added for the last 3 days. Survival was determined by annexin V-FITC/PI staining and flow cytometry, and is shown as percentage relative to DMSO-treated controls.
antiproliferative and proapoptotic effects of the HSP90 inhibitor 17-AAG in HRS cells. However, in this work the response to HSP90 inhibitors was related to downregulation of Akt kinase and inactivation of extracellular signal-regulated kinase. We also demonstrate that siRNA-mediated downregulation of p53, as well as TP53 mutation, renders HRS cells resistant to nutlin-3, but that this does not affect geldanamycin-induced apoptosis in wild-type IkB cells. These observations indicate that the antitumor effects induced by nutlin-3a and geldanamycin are mediated via different and largely independent cell death pathways.
Taken together, our analysis of the p53 pathway in Hodgkin cells shows that p53 signaling was at least partially intact in four out of seven HRS cell lines tested and could be activated by pharmacologic antagonism of p53 inhibitor MDM2. Thus, nongenotoxic activation of p53 might provide a means to help decrease the genotoxic burden of conventional chemotherapies in cHL. The therapeutic effect of MDM2 antagonists might be supported by HSP90 inhibitors, which work through p53-independent mechanisms. This could present an attractive strategy to reduce the incidence of treatment-related secondary cancers. 
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